	Substitute for form 1449A/PTO				Complete if Known		
	INICODMA	TION DISC		IDE	Application Number	10/633,630	
		TION DISC			Filing Date	August 5, 2003	
	STATEME	NIDIAL	-LIC	AN I	First Named Inventor	Jörg Kaufmann	
	(u:	se as many sheet	s as nec	essary)	Art Unit	1635	
					Examiner Name	Kimberly Chong	
(Sheet	1	of	9	Attorney Docket Number	ST-101XT	

			U.S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US- 60/352,873	02-01-2002	Damha, M. J. et al.	All
	U2	US-60/358,580	02-20-2002	Beigelman, L et al.	All
	U3	US-60/363,124	03-11-2002	Beigelman, L. et al.	All
	U4	US-60/386,782	06-06-2002	Beigelman, L. et al.	All
	U5	US-2003/0135033 A1	07-17-2003	Klippel-Giese, A. et al.	All
	U6	US-2004/0106569 A1	06-03-2004	Klippel-Giese, A. et al.	All
	U7	US-2004/0180351 A1	09-16-2004	Giese, K., et al.	All
	U8	US-2005/0043263 A1	02-24-2005	Giese, K., et al.	All
	U9	US-2006/0217329 A1	09-28-2006	Feinstein, E.	All
	U10	US-2006/0240022 A1	10-26-2006	Klippel-Giese, A. et al.	All
	U11	US- 4,217,294	08-12-1980	Petty, H.E.	All
	U12	US- 5,466,786	11-14-1995	Buhr, C. A. et al.	All
	U13	US- 5,589,389	12-31-1996	Pages, E. et al.	All
	U14	US- 5,670,633	09-23-1997	Cook, P. D. et al.	All
	U15	US- 5,792,847	08-11-1998	Buhr, C.A. et al.	All
	U16	US- 5,872,232	02-16-1999	Cook, P.D. et al.	All
	U17	US- 5,898,031	04-27-1999	Crooke, S.T.	All
	U18	US- 5,914,396	06-22-1999	Cook, P.D. et al.	All
	U19	US- 6,005,087	12-21-1999	Cook, P.D. et al.	All
	U20	US- 6,129,912	10-10-2000	Hortin, G. L. et al.	All
	U21	US- 6,153,737	11-28-2000	Manoharan, M. et al.	All
	U22	US- 6,284,267	09-04-2001	Aneja, R.	All
	U23	US- 6,476,205	11-05-2002	Buhr. C. A. et al.	All

Examiner	Date
Signature	Considered
	- Obligation

"EXAMINET. Initial if reference considered, whether or not citation is in conformance with MPEP 600. Date the through citation first in conformance and not considered include copy of this form with next communication to applicate "Applicants" using colation designation number (optional). "Set of Course of the Course of the Course of the Course of Course of the Cou

This collection of information is required by 37 CFR. 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFRO to process) an application. Confidentiality is generated by 38 USFRO to process) an application. Confidentiality is generated by 38 USFRO to process an application. Confidentiality is generated by 38 USFRO to the complete design and use of the complete design and of suggestions for reducing into bediens, should be sent to the Chief information and and and an advantage of the complete design and for suggestions for reducing into bediens, should be sent to the Chief information and and an advantage of the complete design and for suggestions for reducing into bediens, should be sent to the Chief information and an advantage of the complete design and complete support of the complete design and the complete design a

Substitute for fo	rm 1449A/PTO			Complete if Known		
INICODM	ATION DICC			Application Number	10/633,630	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	August 5, 2003	
STATEM	ENIDIAF	PLICAN	•	First Named Inventor	Jörg Kaufmann	
(4	use as many sheet	s as necess	ary)	Art Unit	1635	
				Examiner Name	Kimberly Chong	
Sheet	2	of	9	Attorney Docket Number	ST-101XT	

			U.S. PATENT DO	DCUMENTS	
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U24	US-6,506,559	01-14-2003	Fire, A. et al.	All
	U25	US-6,531,584	03-11-2003	Cook, P.D. et al.	Ali
	U26	US- 6,812,204	11-02-2004	McHale, A. P. et al.	All
	U27	US-7,056,704	06-06-2006	Tuschl, T. et al.	All
	U28	US- 7,074,863	07-11-2006	Ekholm, P. et al.	All
	U29	US- 7,078,196	07-18-2006	Tuschl, T. et al.	All
	U30	US- 7,138,517	11-21-2006	Cook, P.D. et al.	All
	U31	US- 7,148,342	12-12-2006	Tolentino, M. J. et al.	All
	U32	US- 7,196,184	03-27-2007	Heidenreich, O. et al.	All
	U33	US- 2003/0027783	02-06-2003	Zemicka-Goetz, M. et al.	All
	U34	US- 2003/0108923	06-12-2003	Tuschl, T. et al.	All
	U35	US- 2004/0053875	03-18-2004	Kreutzer, R. et al.	All
	U36	US- 2004/0072779	04-15-2004	Kreutzer, R. et al.	All
	U37	US- 2004/0102408	05-27-2004	Kreutzer, R. et al.	All
	U38	US- 2004/0180351	09-16-2004	Giese, K. et al.	All
	U39	US- 2005/0100907	05-12-2005	Kreutzer, R. et al.	All
	U40	US- 2006/0094678	05-04-2006	Vornlocher, H. et al.	All
	U41	US- 2006/0142226	06-29-2006	Polisky, B. et al.	All
	U42	US- 2007/0027097	02-01-2007	Lewis, D. L.	All
	U43	US-2007/0093445	04-26-2007	Tuschl, T. et al.	All
	U44	US- 2007/0135372	06-14-2007	MacLachlan, I. et al.	All
	U45	US- 2007/0265220	11-15-2007	Rossi, J. J. et al.	All
	U46	US- 2004/0175703	09-09-2004	Kreutzer, R. et al.	All
	U47	US-7,348,314	03-25-2008	John, M. et al.	All

Examiner	Date
Signature	Considered
<u></u>	

[&]quot;EXAMINET: Infall if reference considered, whether or not clastion is in conformance with MPEP 600. Draw line through clastion if not in conformance and not considered include copy of this form with next communication to applicate." Applicant unique cluster designation number (optional). See Kind Codes of USFTO Patent Documents at two useful contents of the PEPP 10.4. "Enter Office that issued the document documents the included of the patent document by the appropriate symbols as indicated on the year of the region of the Empirican testing the sentent number of the patent document where the patent document is the patent document of the patent document of the patent document of the patent document and the patent document and the patent document and the patent document of the patent document and the patent docum

This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file gord by the USPTO to proceed) an application. Confidentially is governed by 38 USE C1.22 and 37 CPR 1.14. This collection is astimated to 2 hours to complete, including gathering, preparing, and submitting the completed application from the USPTO. There will vary depending upon the individual caccinery or many on the amount of time you require to complete his form andors suggestions for reducing his budges, should be sent upon to the Information (ISPC). The INFORMATION of the INFORMATION of the INFORMATION (INFORMATION OF INFORMATION OF INFORMATION

Substitute for form	1449A/PTO			Cor	nplete if Known
INFORMA	INFORMATION DISCLOSURE				10/633,630
	NT BY APPL			Filing Date	August 5, 2003
STATEME	NI DI AFFL	.10	AINI	First Named Inventor	Jörg Kaufmann
(us	e as many sheets a	s nec	essary)	Art Unit	1635
				Examiner Name	Kimberly Chong
Sheet	3	of	9	Attorney Docket Number	ST-101XT

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
	F1	EP- 02018572.4	08-14-2002	Atugen AG	All			
	F2	WO 03/064441 A2	08-07-2003	McGill University	All			
	F3	EP- 1 214 945 B1	00-08-2003	Alnylam Europe AG	All	ļ		
	F4	EP- 1 230 375 B1	07-06-2005	Cancer Research Technology Ltd	All			
	F5	EP- 1 407 044 B1	09-19-2007	Max-Planck- Gesellschaft	All			
	F6	EP- 1 798 285 AT	06-20-2007	Ainylam Europe AG	All	 		
	EZ	EP-1 550 719 A1	07.06.2005	Ainylam Europe AG	NA.			
	F8	EP- 1 527 176 B1	01-03-2007	Atugen AG	All			
	F9	GB- 2417727 B	01-16-2008	Alnylam Europe AG	All			
	F10	WO 2007/048244 A2	05-03-2007	Topigen Pharmaceuticals, Inc.	All			
	F11	WO 01/75164 A2	10-11-2001	Whitehead Institute for Biomedical Research et al.	All			
	F12	WO 02/055693 A2	07-18-2002	Ribopharma AG	Abstract On	У		
	F13	WO 2004/015107 A3	02-19-2004	Atugen AG	All			
	F14	WO 2004/019973 A1	03-11-2004	Atugen AG	All			
	F15	WO 2004/035615 A2	04-29-2004	Atugen AG	All			
	F16	WO 2005/000320 A2	01-06-2005	Atugen AG	All			
	F17	WO 2005/105152	11-10-2005	Atugen AG	All			

Examiner	Date
Signature	Considered

"EXAMINES: Intel if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation into in conformance and not considered, include copy of this form with next communication to applicate." Applicant's unique citation designation number (portion): See Kind Obtes of USPTO Patent Documents at https://www.uscuto.org/ or MPEPB01.04. See Kind Cottes of USPTO Patent Documents at https://www.uscuto.org/ or MPEPB01.04. See Kind Cottes of USPTO Patent Documents, the indication of the year of the region of the Conformation of the year of the region of the Conformation of the year of the sear in Jumbor of the pastent occurred fixed of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Transitation is attached of the pastent occurred."

This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is gowered by 39 USC 1.22 and 37 CRR 1.14. This collection is estimated to take 2 plaus to complete including gathering, preparing, and submitting the completed application form to the USPTIO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form ander suggestions for reducing this budges, should be sent to the Chief Information Cities. U.S. Patient and Trademark Office. P.O. Box 1450, Alexandria, VA. 2231-1459. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 41450, Alexandria, VA. 2231-1459.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for for	m 1449A/PTO			Cor	Complete if Known		
INFORM	TION DIOO		.ne	Application Number	10/633,630		
	ATION DISCL ENT BY APPI			Filing Date	August 5, 2003		
STATEMI	ENIDIAFFI	LIG	414 1	First Named Inventor	Jörg Kaufmann		
(u	se as many sheets a	as nec	essary)	Art Unit	1635		
		Examiner Name	Kimberly Chong				
Sheet	4	of	9	Attorney Docket Number	ST-101XT		

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te.					
	F18	WO 2006/023544 A2	03-02-2006	Quark Biotech, Inc. et al.	All						
	F19	WO 2006/069782 A2	07-06-2006	Atugen AG	All						
	F20	WO 2007/084684 A2	07-26-2007	Quark Biotech, Inc. et al.							
	F21										
	F22										
	F23										
	F24										

Examiner	Date	
Signature	Considered	

"EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in gonformance and not considered, include copy of this form with next communication to applicant." Applicant's unique citation designation number (optional)." See Kind Godes of USPTO Parent Decuments at <u>https://decim.pub.org/10.44</u> Einer Citation that issued the document, by the worked the Copy Copy and a common of the Emperor may proceed be search all number of the patient document. "Kind of document by the appropriate symbols as included on the document under WIPO Standard ST. 16 if possible." Applicant is to glace a check mark here if English anguage Translation is assurable.

This collection of Information is required by 37 CPR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to proceed) an application. Condentailable is governed by 38 U.S. C.1. 22 and 37 CPR 1.14. This collection is estimated by Deburst to complete including gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the individual case. Any comments on the amount of time you require to complete his form andors suggestions for reducing this budges, should be sent to the Chief Information Citiesc, U.S. Petant and Tractemark Office, P.D. Box 1450, Alexandria, VA. 2231-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Petents, P.O. Box 4450, Alexandria, VA. 2231-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 14498/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Sheet

Complete if Known					
Application Number	10/633,630				
Filing Date	August 5, 2003				
First Named Inventor	Jörg Kaufmann				
Group Art Unit	1635				
Examiner Name	Kimberly Chong				
Attorney Docket Number	ST-101XT				

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. 1	e Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	R1	AMARZGUIOUI, M. et al. "Tolerance for mutations and chemical modifications in a siRNA", Nucleic Acids Research, 2003, pp. 589-595, Vol. 31, No. 2.					
	R2	BERTRAND, J. et al. "Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo", <i>Biochemical and Biophysical Research Communications</i> , 2002, pp. 1000-1004, Vol. 296.					
	R3	BILLY, E. et al. "Specific interference with gene expression induced by long, double- stranded RNA in mouse embryonal teratocarcinoma cell lines", PNAS, December 4, 2001, pp. 14428-14433, Vol. 98, No. 25.					
	R4	BOUTLA, A. et al. "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in <i>Drosophilla</i> ", <i>Current Biology</i> , November 13, 2001, pp. 1776-1780, Vol. 11.					
	R5	BRAASCH, D.A. et al. "RNA Interference in Mammalian Cells by Chemically-Modified RNA", Biochemistry, 2003, pp. 7967-7975, Vol. 42.					
	R6	BROWN, K. M. et al. "Target accessibility dictates the potency of human RISC", Nature Structural & Molecular Biology, May 2005, pp. 469-470, Vol. 12, No. 5.					
	R7	CHIU, Y. et al. "RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA", Molecular Cell, September 2002, pp. 549-561, Vol. 10.					
	R8	CLAYTON, J. "The Silent Treatment", Nature, September 30, 2004, pp.599-605, Vol. 431.					
	R9	CLEMENS, M. J. "PKR- A Protein Kinase Regulated by Double-stranded RNA", Int. J. Biochem. Cell Biol., 1997, pp. 945-949, Vol. 29, No. 7.					
	R10	CLEMENS, J.C. et al. "Use of double-stranded RNA interference in Drosophilia cell lines to dissect signal transduction pathways", PNAS, June 6, 2000, pp. 6499-6503, Vol. 97, No. 12.					
	R11	CROOKE, R. M. et al. "Metabolism of Antisense Oligonucleotides in Rat Liver Homogenates", The Journal of Pharmacology and Experimental Therapeutics, 2000, pp. 140-149, Vol. 292.					
	R12	CZAUDERNA, F. et al. "Functional Studies of the PI(3)-kinase signaling pathway employing synthetic and expressed siRNA", <i>Nucleic Acids Research</i> , 2003, pp. 670-682, Vol. 31, No. 2.					

Examiner		Date	
Signature		Considered	
*FXAMINER: Initial in	reference considered, whether or not citation is in conformance with MPEP 60	10 Oraw line th	ough citation if not in conformaces

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformal and not considered include copy of this form with next communication to applicant.

and not confidented in control of the control of th

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

9

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) 6

of

Sheet

Cor	nplete if Known	$\overline{}$
Application Number	10/633,630	
Filing Date	August 5, 2003	
First Named Inventor	Jörg Kaufmann	
Group Art Unit	1635	
Examiner Name	Kimberly Chong	
Attorney Docket Number	ST-101XT	

		5 1 5 1 1 1 1 1 1 1	_
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R13	DORSETT, Y. et al. "siRNAs: Applications in Functional Genomics and Potential as Therapeutics", Drug Discovery, April 2004, pp. 318-329, Vol. 3.	
	R14	GARY, D. J. et al. "Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery", <i>Journal of Controlled Release</i> , 2007, pp. 64-73, Vol. 121.	
	R15	HALL, I. M. et al. "Establishment and Maintenance of a Heterochromatin Domain", Science, September 27, 2002, pp. 2232-2237, Vol. 297.	
	R16	HAMMOND, S. M. et al. "Argonaute2, a Link Between Genetic and Biochemical Analyses of RNAi", Science, August 10, 2001, pp. 1146-1150, Vol. 293.	
	R17	HAMMOND, S.M. et al. "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drosophila</i> cells", <i>Nature</i> , March 16, 2000, pp. 293-296, Vol. 404.	
	R18	HANNON, G. J. "RNA interference", <i>Nature</i> , July 11, 2002, pp. 244-251, Vol. 418.	
	R19	HARBORTH, J. et al. "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing", Antisense and Nucleic Acid Drug Development, 2003, pp. 83-105, Vol. 13.	
	R20	HOERTER, J. A. et al. "Chemical Modification Resolves the Asymmetry of siRNA Strand Degradation in Human Blood Serum", RNA, 2007, pp. 1-7, Vol. 13.	
	R21	HU, X. et al. "Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus", <i>Nucleic Acids Research</i> , 2004, pp- 4609-4617, Vol. 32, No. 15.	
	R22	INOUE, A. et al. "Molecular Design and Delivery of siRNA", Journal of Drug Targeting, 2006, pp. 448-455, Vol. 14, No. 7.	
	R23	JACKSON, A. L. et al. "Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing", RNA, 2006, pp. 1197-1205, Vol. 12.	
	R24	KLIPPEL, A. et al. "The Interaction of Small Domains between the Subunits of Phosphatidylinositol 3-Kinase Determines Enzyme Activity", Molecular and Cellular Biology, April 1994, pp. 2675-2685, Vol. 14, No. 4.	

Examiner	Date	
Signature	Considered	
	if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in a	conformance

and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

9

Sheet

7

of

0.1.0	1 0	omplete if Known	
Substitute for form 1449B/PTO INFORMATION DISCLOSURE	Application Number	10/633,630	_
	Filing Date	August 5, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Jörg Kaufmann	
(use as many sheets as necessary)	Group Art Unit	1635	_
(======================================	Examiner Name	Kimberly Chong	_

Attorney Docket Number

ST-101XT

		NON PATENT LITERATURE DOCUMENTS	_				
Examiner Cite No. 1		miner Cite include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the					
	R25	KOLLER, E. et al. "Competition for RISC binding predicts in vitro potency of siRNA", Nucleic Acids Research, 2006, pp. 4467-4476, Vol. 34, No. 16.	T				
	R26	LAYZER, J. M. et al. "In vivo activity of nuclease-resistant siRNAs", RNA, 2004, pp. 766-771, Vol. 10.					
	R27	LEENDERS, F. et al. "PKN3 is required for mallgnant prostate cell growth downstream of activated PI 3-kinase", The EMBO Journal, 2004, pp. 3303-3313, Vol. 23, No. 16.					
	R28	LIMA, W. F. et al. "Structural Requirements at the Catalytic Site of the Heteroduplex Substrate for Human RNase H1 Catalysis", The Journal of Biological Chemistry, August 27, 2004, pp. 36317-36326, Vol. 279, No. 35.					
	R29	LUBINI, P. et al. "Stabilizing effects of the RNA 2'-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2'-O- methylated adenosines", Chemistry & Biology, September 1994, pp. 39-45, Vol. 1.					
	R30	MANOHARAN, M. "RNA interference and chemically modified small interfering RNAs", Current Opinion in Chemical Biology, 2004, pp. 570-579, Vol. 8.					
	R31	MARTINEZ, J. et al. "RISC is a 5' phosphomonoester-producing RNA endonuclease", Genes & Development, 2004, pp. 975-980, Vol. 18.					
	R32	MARTINEZ, J. et al. "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi", Cell, September 6, 2002, pp. 563-574, Vol. 110.					
	R33	MORRISSEY, D. V. et al. "Chemical Modification of Synthetic siRNA", Pharmaceutical Discovery, May 13, 2005.					
	R34	OLIVEIRA, S. et al. "Targeted Delivery of siRNA", Journal of Biomedicine and Biotechnology, 2006, pp. 1-9, Vol. 2006.					
	R35	PADDISON, P. J. <i>et al.</i> "Stable suppression of gene expression by RNAi in mammalian cells", <i>PNAS</i> , February 5, 2002, pp. 1443-1448, Vol. 99, No. 3.					
	R36	PANCOSKA, P. et al. "Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNA", Nucleic Acids Research, 2004, pp. 1469-1479, Vol. 32, No. 4.					

Examiner	Date
Signature	Considered
SEVARABLED. Indies	I at a second at the second at

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicant's urique chation designation number (options). "Applicant is to place a chock mark here if English language Translation is stratched.

This collection of information is required by 50 CFR 1.49. The information is required by that one retain a benefit by the public which is to fie (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including agriculture, and the confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including agriculture, and the confidence application from the tended of the sport of the process of the confidence application from the USPTO. There will vary depending upon the individual case the amount of time you require to complete his form and/or suppessions for reducing this burdent, about do sent to the CRMs information Officer. U.S. Placet and of the process of the CRMs of the USPTO of the USPTO of COMMILETIES OF COMMITTEE OF CRMS TO THIS ADDRESS. SEND TO.

Commissioner for Patents, P.O. Dox 4450, Alexandrica, VA 22313-4460.

				Complete if Known			
	ite for form 1449B/PTO		OCUPE	Application Number	10/633,630		
INFORMATION DISCLOSURE				Filing Date	August 5, 2003		
STATEMENT BY APPLICANT			LICANT	First Named Inventor	Jörg Kaufmann		
(use as many sheets as necessary)				Group Art Unit	1635		
(add as many whoels as hoodsalay)			issaiy)	Examiner Name	Kimberly Chong		
Sheet	8	of	9	Attorney Docket Number	ST-101XT		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R37	PARRISH, S. et al. "Functional Anatomy of a dsRNA Trigger. Differential Requirement for the Two Trigger Strands in RNA Interference", Molecular Cell, November 2000, pp. 1077- 1087, Vol. 6.	
	R38	PATEL, D. J. et al. "Structural Biology of RNA Silencing and Its Functional Implications", Cold Spring Harbor Symposia on Quantitative Biology, 2006, pp. 81-93, Vol. LXXI.	П
	R39	PEEK, A. S. et al. "Design of Active Small Interfering RNAs", Current Opinion in Molecular Therapeutics, 2007, pp. 110-118, Vol. 9, No. 2.	
	R40	PEI, Y. et al. "On the Art of Identifying Effective and Specific siRNAs", Nature Methods, September 2006, pp. 670-676, Vol. 3, No. 9.	
	R41	POTERA, C. "Antisense- down, but not out", <i>Nature Biotechnology</i> , May 2007, pp. 497-499, Vol. 25, No. 5.	
	R42	RANA, T. M. "Illuminating the silence: understanding the structure and function of small RNAs", Molecular Cell Biology, January 2007, pp. 23-36, Vol. 8.	
	R43	RAND, T. A. et al. "Argonaute2 Cleaves the Anti-Guide Strand of siRNA during RISC Activation", Cell, November 18, 2005, pp. 621-629, Vol. 123.	
	R44	ROSSI, J. J. "A Cholesterol connection in RNAi", <i>Nature</i> , November 11, 2004, pp. 155-156, Vol. 432.	
	R45	SANTEL, A. "Get the balance right: Mitofusins roles in health and disease", Biochimica et Biophysica Acta, 2006, pp. 490-499, Vol. 1763.	
	R46	SANTEL, A. et al. "RNA interference in the mouse vascular endothelium by systemic administration of sIRNA-lipoplexes for cancer therapy", Gene Therapy, 2006, pp. 1360-1370, Vol. 13.	П
	R47	SANTEL, A. et al. "A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium", Gene Therapy, 2006, pp. 1222-1234, Vol. 13.	П
	R48	SCHERER, L. J. et al. "Approaches for the sequence-specific knockdown of mRNA", Nature Biotechnology, December 2003, pp. 1457-1465, Vol. 21, No. 12.	П

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{**}EA-WINETE** Intelligence Confessions, winement or not calcided as disconnection of the Mint-Live Visit. Visit with a trought control many formation and the conformation of the Confession of gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the China Tollamation Officer. U.S. Patient and Trademark Office. P.O. Box 1450, Alexandria, W.A. 2233-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

9

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Sheet

Complete if Known				
Application Number	10/633,630			
Filing Date	August 5, 2003			
First Named Inventor	Jörg Kaufmann			
Group Art Unit	1635			
Examiner Name	Kimberly Chong			
Attorney Docket Number	ST-101XT	_		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R49	SCHWARZER, R. et al. "TRB3 is a PI 3-kinase dependent indicator for nutrient starvation", Cellular Signalling, 2006, pp. 899-909, Vol. 18.	
	R50	SNOVE, O. et al. "Chemical Modifications Rescue Off-Target Effects of RNAI", ACS Chemical Biology, 2006, pp. 274-276, Vol. 1, No. 5.	
	R51	TURNER, J. J. et al. "MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity", Molecular BioSystems, 2007, pp. 43-50, Vol. 3.	Γ
	R52	TUSCHL, T. "Expanding small RNA interference", Nature Biotechnology, May 2002, pp. 446-448, Vol. 20.	
	R53	TUSCHL, T. et al. "Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy", Molecular Interventions, June 2002, pp. 158-167, Vol. 2, Issue 3.	
	R54	VOLPE, T. A. et al. "Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi", Science, September 13, 2002, pp. 1833-1837, Vol. 297.	
	R55	WILSON, C. et al. "Building oligonucleotide therapeutics using non-natural chemistries", Current Opinion in Chemical Biology, 2006, pp. 607-614, Vol. 10.	
	Delivery Note, 2 pages, December 20, 2001.		
	R57		
	R58		
	R59		L
	R60		

Examiner	/Kimberly Chong/	Date	05/22/2008
Signature	/Kimberry Griong/	Considered	05/22/2008
*EXAMINER: Initial i	f reference considered, whether or not citation is in conformance w	ith MPEP 609 Draw line th	ough citation if not in conformance

[&]quot;Exchaniser: Intelligent in determination in the control of the co to process) an application. Confidentiality is governed by 30 U.Sc., 122 and 37 CH-T14. This objection is estimated to black 27 flows to complete, including an amount of time you require to complete this form and/or superfixed processing the standard processing the standard flower to the Chief Information Office. U.S. Patient and Trademark Office, P.O. Box 1460, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.